CCXI - ChemoCentryx, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

ChemoCentryx, Inc.

850 Maude Avenue
Mountain View, CA 94043
United States
650-210-2900
http://www.chemocentryx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees76

Key Executives

NameTitlePayExercisedYear Born
Dr. Thomas J. Schall Ph.D.Founder, Pres, CEO & Chairman909.17k2.09M1959
Ms. Susan M. KanayaExec. VP, Chief Financial & Admin. Officer and Sec.656.68k1.16M1963
Dr. Rajinder SinghSr. VP & Head of Pharmaceutics465.34kN/A1967
Dr. Markus J. CappelSr. VP, Chief Bus. Officer & Treasurer546.4k924.2k1961
Dr. Catherine Lee KelleherSr. VP of Clinical Devel.N/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. The company is also developing Avacopan for the treatment of patients with complement 3 glomerulopathy and hidradenitis suppurativa. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis. Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.

Corporate Governance

ChemoCentryx, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.